II. Dosing

  1. Irritable Bowel Syndrome with Constipation: 8 mcg orally twice daily
  2. Chronic Constipation: 24 mcg orally twice daily

III. Adverse Effects

  1. Nausea (with 24 mcg dose)
  2. Diarrhea (with 24 mcg dose)
  3. Chest Pain or Dyspnea
    1. Follows dose within 1 hour
    2. Resolves within 3 hours

IV. Disadvantages

  1. Low efficacy in Irritable Bowel Syndrome with Constipation: Only 14% respond
  2. Expensive: $200 per month

V. Mechanism

  1. ClC(2) chloride channel opener

Images: Related links to external sites (from Bing)

Related Studies

Cost: Medications

amitiza (on 2/22/2017 at Medicaid.Gov Survey of pharmacy drug pricing)

Ontology: lubiprostone (C1684405)

Definition (NCI) A bicyclic fatty acid derived from prostaglandin E1 and a chloride channel activator with laxative activity. Upon intake, lubiprostone specifically binds to and activates the type 2 chloride channel (ClC-2) in the apical membrane of the gastrointestinal epithelium. This produces an efflux of chloride ions, thereby drawing water into the gastrointestinal lumen. The resulting increased amounts of intestinal fluid soften the stool, increase motility, and improve bowel movements.
Concepts Pharmacologic Substance (T121) , Eicosanoid (T111)
MSH C506401
SnomedCT 420304008, 421856003
English Lubiprostone, Lubiprostone (product), Lubiprostone (substance), 7-((1R,4R,6R,9R)-4-(1,1-difluoropentyl)-4-hydroxy-8-oxo-5-oxabicyclo(4.3.0)non-9-yl)heptanoic acid, Prostan-1-oic acid, 16,16-difluoro-11-hydroxy-9,15-dioxo-, (11alpha)-, lubiprostone (medication), lubiprostone [Chemical/Ingredient], LUBIPROSTONE, lubiprostone
Spanish lubiprostona, lubiprostona (producto), lubiprostona (sustancia)

Ontology: Amitiza (C1699150)

Concepts Lipid (T119) , Pharmacologic Substance (T121)
MSH C506401
English Amitiza